Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naive ALK plus advanced NSCLC C. Zhou, Y. Lu,S-W. Kim,T. Reungwetwattana, J. Zhou,Y. Zhang,J. He,J. J. Yang,Y. Cheng,S. H. Lee, L. Bu,T. Xu,L. Yang,C. Wang,P. N. Morcos,E. Mitry,T. Liu,L. ZhangANNALS OF ONCOLOGY(2018)引用 21|浏览21暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络